Abstract:Introduction: Chimeric antigen receptor (CAR) T-cell therapy is an emerging therapeutic option for cancer treatment. However, its efficacy is limited, especially in solid tumors. This is partly because the CAR T cells become dysfunctional and exhausted in the tumor microenvironment. However, the key pathways responsible for impaired function of exhausted T cells remain unclear. Immunosuppressive cytokines or checkpoint proteins like TGF-β and PD-L1, are overproduced, which may lead to the downregulation of CD8+ T cell action and the promotion of T-reg maturation. E3 ligase Casitas B-Lineage Lymphoma Proto-Oncogene B (CBL-B) is a key negative modulator of T/NK-cell receptor and co-stimulatory regulation. CBL-B inhibition lowers the threshold of antigen-specific T/NK cell activation, even in absence of co-stimulatory signaling or the presence of an immune suppressive environment. Genetic ablation of CBL-B or functional inactivation of its E3 ligase activity in mice or primary human T cells enhances immune-mediated tumor growth control. Therefore, CBL-B inhibition may address the suboptimal response to current immunotherapies due to low inflammation, no/low co-stimulation signal or a high immune suppressive environment. Several groups demonstrated that deficiency of CBL-B overcomes endogenous CD8+ T-cell exhaustion, and deletion of CBL-B in CAR-T cells renders them resistant to exhaustion and deletion of CBL-B in CAR-NK cells provides greater resistance to TGF-β. Methods: We tested the CAR expression, T/NK cell activation and in vitro cytotoxicity when ex vivo culture of CAR-T or CAR-NK cells with CBL-B inhibitors. Results: We demonstrated that the combination of CBL-B inhibitor and CAR-NK cells elicited remarkable persistence in multiple runs of repeated cancer cell clearance assay, as compared to CAR-NK cells alone. Moreover, the combination of CAR-NK cells with both anti-PDL1-IL15 and CBL-B inhibitor showed further increased persistence in repeated cancer cell clearance assay. Conclusions: preclinical data provided evidence of CBL-B inhibitors to enhance key parameters associated with T/NK cell activation and reduce susceptibility to immune suppression. Our results suggest the combination strategy of cell therapy and immune regulating small/large molecule therapy might achieve better anti-tumor efficacy in both hematological and solid tumors. Citation Format: Cuiqing Yang, Yifang Wang, Tingting Liu, Fuwei Jiang, Chao Wang, Qingyang Wang, Qin Wang, Zhengtao Li, Wansun Mai, Gang Ye, Renhong Tang, Zhuoxiao Cao. Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited s); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl) nr 2899.

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

Targeting Cbl-b in cancer immunotherapy

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors

Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

Genomic Profiling Reveals Immune-Related Gene Differences in Lung Cancer Patients Stratified by PD1/PDL1 Expression: Implications for Immunotherapy Efficacy

Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Lymphocyte activation gene-3 as a candidate target for combo anti-programmed death-(ligand) 1 therapy of cancer

Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)

CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

Abstract 2899: Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies

A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.

N-terminal Acetylation of Transcription Factor LIP Induces Immune Therapy Resistance Via Suppression of PD-L1 Expression in Non-Small Cell Lung Cancer

High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)